The PROCARE consortium
| Autor: | Luuk B. Hilbrands, E.M. van Duijnhoven, Frans H.J. Claas, Azam S. Nurmohamed, Jan-Stephan F. Sanders, Michiel L. Bots, M. A. Seelen, Maarten H. L. Christiaans, Wendy Swelsen, I. J. M. ten Berge, F. J. van Ittersum, A. F. G. van der Meer, Marije C. Baas, N. C. van der Weerd, Caroline Roozendaal, Henderikus G. Otten, Annechien J. A. Lambeck, Joris Vanderlocht, Marcel G.J. Tilanus, Andries J. Hoitsma, D.L. Roelen, Michiel G. H. Betjes, F. J. Bemelman, Bouke G. Hepkema, J.W. de Fijter, Eric Spierings, N M Lardy, Wil A. Allebes, Irma Joosten, Marianne C. Verhaar, M. Gelens, Lotte Wieten, Laura Bungener, A D van Zuilen, Christien Voorter, F. van Reekum, K. A. M. I. van Donselaar-van der Pant, Cornelis E. Hack |
|---|---|
| Přispěvatelé: | Nephrology, AII - Amsterdam institute for Infection and Immunity, ICaR - Circulation and metabolism, Groningen Institute for Organ Transplantation (GIOT), Groningen Kidney Center (GKC), Interne Geneeskunde, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Oral and Maxillofacial Surgery, Plastic and Reconstructive Surgery and Hand Surgery, Erasmus MC other, Epidemiology, Internal Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Graft Rejection
Oncology medicine.medical_treatment Epitopes T-Lymphocyte Kidney T and B cell epitopes COMPLEMENT Kidney transplantation HLA Antigens Clinical endpoint Immunology and Allergy RENAL-TRANSPLANTATION Histocompatibility Testing Graft Survival Gene polymorphisms HLA antibodies medicine.anatomical_structure REJECTION Epitopes B-Lymphocyte Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] medicine.medical_specialty Tissue and Organ Procurement Waiting Lists Immunology Renal function Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0] Human leukocyte antigen DONOR Renal Dialysis RISK-FACTOR Internal medicine medicine Humans Organ donation CELL Dialysis Autoantibodies Transplantation RECEPTOR IDENTIFICATION business.industry Other Research Radboud Institute for Health Sciences [Radboudumc 0] medicine.disease Quality of Life Kidney Failure Chronic NON-HLA ANTIBODIES IMMUNOGLOBULIN-G Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] Donor registration business |
| Zdroj: | Transplant Immunology, 31, 4, pp. 184-90 Transplant immunology, 31(4), 184-190. Elsevier Transplant Immunology, 31(4), 184-190. Elsevier Transplant Immunology, 31(4), 184-190 Otten, H G, Joosten, I, Allebes, W A, van der Meer, A, Hilbrands, L B, Baas, M, Spierings, E, Hack, C E, van Reekum, F, van Zuilen, A D, Verhaar, M C, Bots, M L, Seelen, M A J, Sanders, J S F, Hepkema, B G, Lambeck, A J, Bungener, L B, Roozendaal, C, Tilanus, M G J, Vanderlocht, J, Voorter, C E, Wieten, L, van Duijnhoven, E, Gelens, M, Christiaans, M, van Ittersum, F J, Nurmohamed, S A, Lardy, N M, Swelsen, W T, van Donselaar-v Pant, K A, van der Weerd, N C, ten Berge, I J M, Bemelman, F J, Hoitsma, A J, de Fijter, J W, Betjes, M G H, Roelen, D L & Claas, F H J 2014, ' The PROCARE consortium: Toward an improved allocation strategy for kidney allografts ', Transplant Immunology, vol. 31, no. 4, pp. 184-190 . https://doi.org/10.1016/j.trim.2014.09.008 Transplant Immunology, 31, 184-90 |
| ISSN: | 0966-3274 |
| DOI: | 10.1016/j.trim.2014.09.008 |
| Popis: | Kidney transplantation is the best treatment option for patients with end-stage renal failure. At present, approximately 800 Dutch patients are registered on the active waiting list of Eurotransplant The waiting time in the Netherlands for a kidney from a deceased donor is on average between 3 and 4 years. During this period, patients are fully dependent on dialysis, which replaces only partly the renal function, whereas the quality of life is limited. Mortality among patients on the waiting list is high. In order to increase the number of kidney donors, several initiatives have been undertaken by the Dutch Kidney Foundation including national calls for donor registration and providing information on organ donation and kidney transplantation. The aim of the national PROCARE consortium is to develop improved matching algorithms that will lead to a prolonged survival of transplanted donor kidneys and a reduced HLA immunization. The latter will positively affect the waiting time for a retransplantation. The present algorithm for allocation is among others based on matching for HLA antigens, which were originally defined by antibodies using serological typing techniques. However, several studies suggest that this algorithm needs adaptation and that other immune parameters which are currently not included may assist in improving graft survival rates. We will employ a multicenter-based evaluation on 5429 patients transplanted between 1995 and 2005 in the Netherlands. The association between key clinical endpoints and selected laboratory defined parameters will be examined, including Luminex-defined HLA antibody specificities, T and B cell epitopes recognized on the mismatched HLA antigens, non-HLA antibodies, and also polymorphisms in complement and Fc receptors functionally associated with effector functions of anti-graft antibodies. From these data, key parameters determining the success of kidney transplantation will be identified which will lead to the identification of additional parameters to be included in future matching algorithms aiming to extend survival of transplanted kidneys and to diminish HLA immunization. Computer simulation studies will reveal the number of patients having a direct benefit from improved matching, the effect on shortening of the waiting list, and the decrease in waiting time. (C) 2014 Published by Elsevier B.V. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect